Medine.co.uk

Out of date information, search another

Potters Skin Clear Tea Tree Ointment

Out of date information, search another
Informations for option: Potters Skin Clear Tea Tree Ointment, show other option

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Potter’s Skin Clear Tea Tree Ointment

2    QUALITATIVE AND QUANTITATIVE COMPOSITION

1 g of ointment contains:

0.1 % w/w Tea Tree Oil (Melaleuca alternifolia (Maiden and Betche) Cheel)

23.0    % w/w Zinc Oxide

5.0    % w/w Sublimed Sulphur

For full list of excipients see Section 6.1

3    PHARMACEUTICAL FORM

Cutaneous ointment.

Cream coloured ointment

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

A traditional herbal medicinal product used for the symptomatic relief of minor skin conditions such as spots, pimples, and blemishes, based on traditional use only.

4.2 Posology and method of administration

For cutaneous use only.

Wash hands before and after use.

Adults, the elderly and children over 12 years: Apply ointment sparingly once in the morning and once at night.

Not recommended for children under 12 years of age. (See section 4.4 ‘Special warnings and precautions for use’).

If symptoms worsen or persist for more than 2 weeks a doctor or a qualified health care practitioner should be consulted.

4.3 Contraindications

Hypersensitivity to the active ingredients or any of the excipients.

4.4 Special warnings and precautions for use

Do not exceed the stated dose.

Avoid contact with eyes and mucous membranes.

Do not use on broken or irritated skin.

If symptoms worsen or if signs of infection are observed or if symptoms do not improve after 2 weeks a doctor or a qualified health care practitioner

should be consulted.

Discontinue use if skin reaction, irritation or dry skin occurs and consult a doctor or a qualified health care practitioner.

Not recommended for children under 12 years of age because data are not sufficient and medical advice should be sought.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established. Therefore in the absence of sufficient data, the use of this product during pregnancy and lactation is not recommended.

Studies on fertility have not been performed.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive or use machines have been performed

4.8 Undesirable effects

None known.

If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

Overdose

4.9


No case of overdose has been reported.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2 Pharmacokinetic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3 Preclinical safety data

Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6 PHARMACEUTICAL PARTICULARS

6.1    List of excipients

Yellow Soft Paraffin Maize Starch

6.2    Incompatibilities

None

6.3    Shelf life

3 years

6.4


Special precautions for storage

Do not store above 25°C. Store in the original container.

6.5 Nature and contents of container

Amber glass jar with hard plastic screwcap: 30 g and 55 g. Double-wall plastic jar with hard plastic screwcap: 30 g and 55 g. Polypropylene jar with polypropylene closure: 40 g, 50 g and 55 g. Not all pack sizes may be marketed.

6.6 Special precautions for disposal

There are no special precautions for disposal.

7    MARKETING AUTHORISATION HOLDER

Vifor Pharma UK Ltd 1 Botanic Court,

Martland Park,

Wigan,

WN5 0JZ,

UK.

Trading as: Potters, Wigan WN5 0JZ

8    MARKETING AUTHORISATION NUMBER(S)

THR 33656/0065

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

12/04/2013

10 DATE OF REVISION OF THE TEXT

12/04/2013